The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Radiofrequency Ablation vs Endoscopic Surveillance for Patients With Barrett Esophagus and Low-Grade Dysplasia: A Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: Barrett esophagus containing low-grade dysplasia is associated with an increased risk of developing esophageal adenocarcinoma, a cancer with a rapidly increasing incidence in the western world. OBJECTIVE: To investigate whether endoscopic radiofrequency ablation could decrease the rate of neoplastic progression. DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized clinical trial that enrolled 136 patients with a confirmed diagnosis of Barrett esophagus containing low-grade dysplasia at 9 European sites between June 2007 and June 2011. Patient follow-up ended May 2013. INTERVENTIONS: Eligible patients were randomly assigned in a 1:1 ratio to either endoscopic treatment with radiofrequency ablation (ablation) or endoscopic surveillance (control). Ablation was performed with the balloon device for circumferential ablation of the esophagus or the focal device for targeted ablation, with a maximum of 5 sessions allowed. MAIN OUTCOMES AND MEASURES: The primary outcome was neoplastic progression to high-grade dysplasia or adenocarcinoma during a 3-year follow-up since randomization. Secondary outcomes were complete eradication of dysplasia and intestinal metaplasia and adverse events. RESULTS: Sixty-eight patients were randomized to receive ablation and 68 to receive control. Ablation reduced the risk of progression to high-grade dysplasia or adenocarcinoma by 25.0% (1.5% for ablation vs 26.5% for control; 95% CI, 14.1%-35.9%; P < .001) and the risk of progression to adenocarcinoma by 7.4% (1.5% for ablation vs 8.8% for control; 95% CI, 0%-14.7%; P = .03). Among patients in the ablation group, complete eradication occurred in 92.6% for dysplasia and 88.2% for intestinal metaplasia compared with 27.9% for dysplasia and 0.0% for intestinal metaplasia among patients in the control group (P < .001). Treatment-related adverse events occurred in 19.1% of patients receiving ablation (P < .001). The most common adverse event was stricture, occurring in 8 patients receiving ablation (11.8%), all resolved by endoscopic dilation (median, 1 session). The data and safety monitoring board recommended early termination of the trial due to superiority of ablation for the primary outcome and the potential for patient safety issues if the trial continued. CONCLUSIONS AND RELEVANCE: In this randomized trial of patients with Barrett esophagus and a confirmed diagnosis of low-grade dysplasia, radiofrequency ablation resulted in a reduced risk of neoplastic progression over 3 years of follow-up. TRIAL REGISTRATION: trialregister.nl Identifier: NTR1198.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Vienna classification of gastrointestinal epithelial neoplasia
Schlemper, R. J., Riddell, R. H., Kato, Y., Borchard, F., Cooper, H. S., Dawsey, S. M., Dixon, M. F., Fenoglio-Preiser, C. M., Fléjou, J.-F., Geboes, K., et al. (2000) · Gut · doi:10.1136/gut.47.2.251 · Cited by 2,138
Radiofrequency Ablation in Barrett's Esophagus with Dysplasia
Shaheen, N. J., Sharma, P., Overholt, B. F., Wolfsen, H. C., Sampliner, R. E., Wang, K. K., Galanko, J. A., Bronner, M. P., Goldblum, J. R., Bennett, A. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808145 · Cited by 1,438
Incidence of Adenocarcinoma among Patients with Barrett's Esophagus
Hvid-Jensen, F., Pedersen, L., Drewes, A. M., Sørensen, H. T., & Funch-Jensen, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103042 · Cited by 1,371
Pohl, H., & Welch, H. G. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji024 · Cited by 1,270
Sharma, P., Dent, J., Armstrong, D., Bergman, J. J. G. H. M., Gossner, L., Hoshihara, Y., Jankowski, J. A., Junghard, O., Lundell, L., Tytgat, G. N. J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.032 · Cited by 1,049
Self-citation(2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.030 · Cited by 1,009
Prevalence of Barrett’s Esophagus in the General Population: An Endoscopic Study
Ronkainen, J., Aro, P., Storskrubb, T., Johansson, S., Lind, T., Bolling–Sternevald, E., Vieth, M., Stolte, M., Talley, N. J., & Agréus, L. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.08.053 · Cited by 940
Bhat, S., Coleman, H. G., Yousef, F., Johnston, B. T., McManus, D. T., Gavin, A. T., & Murray, L. J. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr203 · Cited by 741
Our new president—Jon I. Isenberg, M.D
Boland, C. R., & Yamada, T. (2001) · Gastroenterology · doi:10.1053/gast.2001.24057 · Cited by 629
Low-Grade Dysplasia in Barrett's Esophagus: Overdiagnosed and Underestimated
Curvers, W. L., ten Kate, F. J., Krishnadath, K. K., Visser, M., Elzer, B., Baak, L. C., Bohmer, C., Mallant-Hent, R. C., van Oijen, A., Naber, A. H., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.171 · Cited by 463
Self-citation
Cited by
ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus
Shaheen, N. J., Falk, G. W., Iyer, P. G., & Gerson, L. B. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.322 · Cited by 1,501
Smyth, E. C., Lagergren, J., Fitzgerald, R. C., Lordick, F., Shah, M. A., Lagergren, P., & Cunningham, D. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.48 · Cited by 1,012
Heating technology for malignant tumors: a review
Kok, H. P., Cressman, E. N. K., Ceelen, W., Brace, C. L., Ivkov, R., Grüll, H., ter Haar, G., Wust, P., & Crezee, J. (2020) · International Journal of Hyperthermia · doi:10.1080/02656736.2020.1779357 · Cited by 422
Duits, L. C., Phoa, K. N., Curvers, W. L., ten Kate, F. J. W., Meijer, G. A., Seldenrijk, C. A., Offerhaus, G. J., Visser, M., Meijer, S. L., Krishnadath, K. K., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-307278 · Cited by 286
Self-citationGenomic copy number predicts esophageal cancer years before transformation
Killcoyne, S., Gregson, E., Wedge, D. C., Woodcock, D. J., Eldridge, M. D., de la Rue, R., Miremadi, A., Abbas, S., Blasko, A., Kosmidou, C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1033-y · Cited by 149
Metadata
- Authors
- Phoa, K. N., van Vilsteren, F. G. I., Weusten, B. L. A. M., Bisschops, R., Schoon, E. J., Ragunath, K., Fullarton, G., Di Pietro, M., Ravi, N., Visser, M., Offerhaus, G. J., Seldenrijk, C. A., Meijer, S. L., ten Kate, F. J. W., Tijssen, J. G. P., & Bergman, J. J. G. H. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-03-26
- Volume
- 311
- Issue
- 12
- Pages
- 1209
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2159594443
- Cited by
- 640
- References
- 24
- FWCI
- 68.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radiofrequency Ablation vs Endoscopic Surveillance for Patients With Barrett Esophagus and Low-Grade Dysplasia: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2014.2511
- The paper
- Phoa, K. N., van Vilsteren, F. G. I., Weusten, B. L. A. M., Bisschops, R., Schoon, E. J., Ragunath, K., Fullarton, G., Di Pietro, M., Ravi, N., Visser, M., Offerhaus, G. J., Seldenrijk, C. A., Meijer, S. L., ten Kate, F. J. W., Tijssen, J. G. P., & Bergman, J. J. G. H. M. (2014). Radiofrequency Ablation vs Endoscopic Surveillance for Patients With Barrett Esophagus and Low-Grade Dysplasia: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2014.2511
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.